Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2014 / Articles / Nov / Antibiotic Action
Manufacture Small Molecules Business Practice Trends & Forecasts Business & Trends

Antibiotic Action

Organizations all over the globe are taking action against drug resistance. Tracey Guise of the British Society for Antimicrobial Chemotherapy (BSAC) is positive about the latest developments.

By Tracey Guise 11/10/2014 0 min read

Share

How are different countries tackling the issue? There has been a slowly growing groundswell from academic and learned organization initiatives in recent years that has led to heightened interest and action from politicians across the globe. The Transatlantic Taskforce on Antimicrobial Resistance was established by US Presidential declaration in 2009 and issued its first report in September 2012, identifying the need for intensified cooperation between the US and Europe. In the European Union, the EMA has been reviewing the requirements for clinical trials of antibacterial treatments, while in India the publication of the Chennai Declaration led to changes in Indian law aimed at ending the sale of over-the-counter antibiotics. In the UK, the topic of drug resistance remains high on the political agenda – mainly thanks to the efforts of Chief Medical Officer Dame Sally Davies leading global role, Antibiotic Action and the All Party Parliamentary Committee on Antibiotics (of which BSAC is the secretariat). In 2013, both the World Health Organization and the UK government published their five-year strategies on antimicrobial resistance, while in July 2014, UK Prime Minister David Cameron declared the need for urgent and global action as he announced the launch of a commission on antibiotic resistance.

How bleak is the situation?

Despite the difficulties in discovering and bringing new antibiotics to market, we are hopeful that new antibiotics will be discovered and brought to market. Regulatory changes, such as those afforded by the GAIN initiative in the US, are helping to incentivize antibiotic development and the return of pharmaceutical companies to the space.

What is the most exciting initiative so far?

Perhaps most exciting of all is the recent announcement that antibiotics won the vote for the UK’s £10-million Longitude Prize challenge. It’s exciting because it was a public vote that secured success. Public action is perhaps the least used but potentially most powerful way to demand and ensure action on resistance.

Read more about antimicrobial drug development here.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Tracey Guise

Tracey Guise is ‎Chief Executive Officer at British Society for Antimicrobial Chemotherapy.

More Articles by Tracey Guise

False

Advertisement

Recommended

False

Related Content

The Final Frontier?
Small Molecules
The Final Frontier?

December 1, 2014

0 min read

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Calculate – Don’t Estimate – Drug Development Costs
Small Molecules
Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

0 min read

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.